Advertisement
Australia markets closed
  • ALL ORDS

    8,082.30
    -67.80 (-0.83%)
     
  • ASX 200

    7,814.40
    -66.90 (-0.85%)
     
  • AUD/USD

    0.6695
    +0.0015 (+0.22%)
     
  • OIL

    80.00
    +0.77 (+0.97%)
     
  • GOLD

    2,419.80
    +34.30 (+1.44%)
     
  • Bitcoin AUD

    100,192.53
    +366.98 (+0.37%)
     
  • CMC Crypto 200

    1,372.08
    -1.77 (-0.13%)
     
  • AUD/EUR

    0.6155
    +0.0016 (+0.26%)
     
  • AUD/NZD

    1.0905
    -0.0001 (-0.01%)
     
  • NZX 50

    11,699.79
    -28.27 (-0.24%)
     
  • NASDAQ

    18,546.23
    -11.73 (-0.06%)
     
  • FTSE

    8,420.26
    -18.39 (-0.22%)
     
  • Dow Jones

    40,003.59
    +134.21 (+0.34%)
     
  • DAX

    18,704.42
    -34.39 (-0.18%)
     
  • Hang Seng

    19,553.61
    +177.08 (+0.91%)
     
  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

Phreesia Full Year 2024 Earnings: In Line With Expectations

Phreesia (NYSE:PHR) Full Year 2024 Results

Key Financial Results

  • Revenue: US$356.3m (up 27% from FY 2023).

  • Net loss: US$136.9m (loss narrowed by 22% from FY 2023).

  • US$2.51 loss per share (improved from US$3.36 loss in FY 2023).

revenue-and-expenses-breakdown
revenue-and-expenses-breakdown

All figures shown in the chart above are for the trailing 12 month (TTM) period

Phreesia Meets Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.

In the last 12 months, the only revenue segment was Healthcare Software contributing US$356.3m. The largest operating expense was Sales & Marketing costs, amounting to US$147.0m (40% of total expenses). Explore how PHR's revenue and expenses shape its earnings.

ADVERTISEMENT

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US.

Performance of the American Healthcare Services industry.

The company's shares are down 4.8% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 3 warning signs for Phreesia that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.